Omega-3-Derived Molecule May Help Body Fight Pneumonia While Reducing Lung Damage
This laboratory study looked at Resolvin D5 (RvD5), a molecule the body naturally makes from omega-3 fatty acids during infection and inflammation. Researchers studied its effects in mice with severe pneumococcal pneumonia, a serious lung infection caused by Streptococcus pneumoniae bacteria.
When given at the start of infection, RvD5 reduced the buildup of neutrophils (a type of immune cell) in the lungs, helped the body clear the bacteria more effectively, and reduced markers of lung tissue damage. When given after infection alongside the antibiotic ceftriaxone, RvD5 further reduced immune cell buildup and helped preserve the integrity of the lung’s air-sac barrier compared to antibiotic treatment alone.
In lab tests using human immune cells, RvD5 also improved the ability of neutrophils to engulf and destroy bacteria, while dampening an overactive inflammatory signal (LTB4) that can contribute to excessive immune responses.
What this means for you
This early-stage research, conducted in mice and human cells in a lab setting, suggests that resolvins—specialized molecules derived from omega-3 fatty acids—may help the body both fight infection and limit collateral tissue damage during severe respiratory infections. It has not yet been tested in humans with pneumonia, so it should be viewed as promising foundational science rather than evidence that omega-3 supplements treat or prevent lung infections.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
Clinical science (London, England : 1979) · 2026-09-09 · DOI: 10.1042/CS20261424
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.